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Aims Endothelial activation, macrophage infiltration, and foam cell formation are pivotal steps in atherogenesis. Our aim in
this study was to analyse the role of SIRT1, a class III deacetylase with important metabolic functions, in plaque
macrophages and atherogenesis.
Methods
and results
Using partial SIRT1 deletion in atherosclerotic mice, we demonstrate that SIRT1 protects against atherosclerosis by
reducing macrophage foam cell formation. Peritoneal macrophages from heterozygous SIRT1 mice accumulate more
oxidized low-density lipoprotein (oxLDL), thereby promoting foam cell formation. Bone marrow-restricted SIRT1
deletion confirmed that SIRT1 function in macrophages is sufficient to decrease atherogenesis. Moreover, we
show that SIRT1 reduces the uptake of oxLDL by diminishing the expression of lectin-like oxLDL receptor-1 (Lox-1)
via suppression of the NF-kB signalling pathway.
Conclusion Our findings demonstrate protective effects of SIRT1 in atherogenesis and suggest pharmacological SIRT1 activation
as a novel anti-atherosclerotic strategy by reducing macrophage foam cell formation.
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Introduction
Atherosclerosis is a chronic inflammatory disease that results from
interaction between oxidized low-density lipoprotein (oxLDL),
activated endothelial cells, monocyte-derived macrophages, T
cells, and the arterial wall. Activated endothelial cells express
adhesion molecules, e.g. vascular cell adhesion molecule 1
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1),
which attract and recruit blood monocytes to the vessel wall.
These monocytes differentiate into macrophages and infiltrate to
the sub-endothelial space where they release and respond to
inflammatory mediators such as tumour necrosis factor-a
(TNFa), VCAM-1, and interleukins (IL). Eventually, these inflamma-
tory macrophages ingest oxLDL via scavenger receptors, such as
scavenger receptor-A (SR-A), CD36 or lectin-like oxLDL receptor
1 (Lox-1), becoming foam cells, and thereby promoting plaque
formation.1
Sir2 is an NAD-dependent class III deacetylase that was found to
increase lifespan in yeast.2 Its mammalian orthologue SIRT1 senses
caloric restriction, improves insulin secretion in pancreatic beta
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cells, and reduces accumulation of fatty acids in white adipose
tissue (WAT).3–5 Various targets of SIRT1 have been character-
ized, including PPARg coactivator 1a (PGC-1a), nuclear factor
kB (NF-kB), p53, FOXO transcription factors, and endothelial
nitric oxide synthase (eNOS).6–13 Interestingly, many of these
targets that are critically involved in regulating metabolism have
also been shown to play a role in atherogenesis.14–18 However,
little is known about the relevance of SIRT1 in the latter.
In atherogenesis, chronic endothelial dysfunction is a trigger of
plaque formation,19 and endothelial SIRT1 overexpression has been
shown to prevent atherosclerosis by improving vascular function.20
Nevertheless, the relevance of SIRT1 on the cellular and molecular
events governing atherogenesis is unknown. As multiple targets of
SIRT1 may play a role in plaque formation, it is likely that eNOS is
not the only mechanism by which SIRT1 prevents atherogenesis. In
particular, the role of SIRT1 in monocyte adhesion, macrophage infil-
tration, lipid uptake, and foam cell formation remains to be
determined.
To investigate the role of SIRT1 in these cellular and molecular
processes, we compared hypercholesterolaemic ApoE2/2
SIRT1+/+ with ApoE2/2 SIRT1+/2 mice. These mice have an
SIRT1 haploinsufficiency, but do not display the autoimmune and
dysmorphic phenotype of SIRT12/2 mice.21,22
Methods
Animals
SIRT1 knockout mice on a 129 background22 were crossed into
ApoE2/2 C57BL/6 mice23 to generate ApoE2/2 SIRT1+/2 mice and
ApoE2/2 SIRT1+/+ littermates. Of those, male mice were fed a high-
cholesterol diet (1.25% total cholesterol, Research Diets) for 12
weeks starting at the age of 8 weeks. Because the few ApoE2/2
SIRT12/2 mice showed a similar dysmorphic phenotype as SIRT12/2
mice,21,22 we did not use them in this study. All animal procedures
were approved by the local animal committee and performed in
accordance with our institutional guidelines.
Bone marrow transplantation
Bone marrow donor mice were ApoE2/2 SIRT1+/2 (n ¼ 3; pooled) and
ApoE2/2 SIRT1+/+ (n ¼ 3; pooled) mice, and recipients pure ApoE2/2
mice (from Jackson Laboratories). Donor mice were split—
dose-irradiated under SPF conditions in filter cages with a total
irradiation of 1100 rad.24 Recipient mice were injected intravenously
with 106 bone marrow cells (ApoE2/2 SIRT1+/27 ApoE2/2 mice;
ApoE2/2 SIRT1+/+6 ApoE2/2 mice). Transplanted mice recovered
for 5 weeks and were then fed a high-cholesterol diet for 11 weeks.
Lipoprotein uptake
RAW 264.7 and thioglycolate-elicited peritoneal macrophages were
starved for 48 h and then incubated with 10 mg/mL oxLDL for 2 h at
378C/5% CO2. After washing away unspecifically bound LDL, cells
were fixed and stained with Oil red O (ORO). Experiments were
done twice with six independent pools isolated from six mice of
each genotype, ORO staining analysed using a light microscope and
quantified using analySIS. Low-density lipoprotein uptake was quanti-
fied as the ratio of the percentage of the ORO-positive area divided
by the percentage of the total cell area in at least 150 cells per geno-
type. For CD36 blocking studies, RAW 264.7 macrophages were first
pre-stimulated for 5 h with 10 ng/mL murine TNFa, and then pre-
incubated with 2 mg/mL mouse anti-CD36 (Cascade Bioscience)
before adding 10 mg/mL oxLDL over night.
Cell culture
Murine RAW 264.7 cells (Mouse leukaemic monocyte macrophage cell
line) were treated with 200 mM splitomicin (Sigma-Aldrich) to perform
cholesterol efflux and oxLDL uptake studies. RAW 264.7 cells were
stimulated for with 10 ng/mL murine TNFa for 5 h. SIRT12/2 mouse
embryonic fibroblasts (MEF)25 were kindly provided by Frederick
W. Alt (Harvard University, Boston, MA, USA), and RelA/p652/2
MEF with reconstituted wt-RelA/p65 or non-acetylatable RelA/p65
were described previously.26
Plasmid and siRNA transfection
Transient transfection of pcDNA3.1::SIRT1 or siRNA into RAW 264.7
or MEF were done with lipofectamin 2000 or lipofectamin RNAi MAX
(both Invitrogen). The oligos used for SIRT1-siRNA have been
described previously.5
Immunohistochemistry and
immunocytochemistry
Serial cryosections from the aortic sinus were stained with ORO, rat
anti-CD68, rat anti-CD3 (Abcam), rat anti-CD31, rabbit anti-SIRT1
(Upstate/Millipore). Means were taken from n ¼ 6 different mice eval-
uating six serial cryosections/tissue from each mouse. Thoraco-
abdominal aortae were fixed and plaques stained with ORO. Collagen,
fibrous cap thickness, and necrotic core size were analysed by Elastica
van Gieson and Massons trichrome stainings. Cell death was assessed
with the terminal deoxyribonucleotidyl transferase-mediated dUTP
nick-end labelling kit (Roche).
RNA and protein analysis
Total RNA isolated from proximal aortae was extracted with TRIZOL
(Invitrogen), reverse transcribed, and the cDNA quantified by SYBR
green qPCR using specific primers. For protein analysis, aortic tissue
lysates were blotted and incubated with rabbit anti-SIRT1 (Upstate/
Millipore), rabbit anti-eNOS, rabbit anti-phospho-eNOS (Ser1177).
Cholesterol efflux
For cholesterol efflux experiments, RAW 264.7 cells were labelled
with 2 mCi/mL [1,2-3H]cholesterol (Perkin Elmer) for 24 h. Following
the labelling period, cells were washed and allowed to equilibrate over-
night in DMEM containing 0.2% BSA supplemented with cholesterol in
the presence or absence of 0.1 mM splitomicin together with 0.3 mM
8-Br-cAMP or 22(R)-HC and 9-cisRA (Sigma). After 24 h stimulation,
cells were washed and incubated for 6 h in DMEM containing 0.2%
BSA in the presence or absence of 28 mg/mL lipid-free apoA-I. The
radioactivity recovered in the culture medium and cell lysates was
measured. The apoA-I-mediated cholesterol efflux was calculated as
the percentage of total [1,2-3H]cholesterol released into the
medium after subtracting the values obtained in the absence of
apoA-I. The cholesterol efflux assays were performed in duplicates
with three pairs per treatment group.
Plasma lipids and cytokines
Total plasma cholesterol, triglycerides, and free fatty acids were ana-
lysed using TR13421, TR22421 (Thermo Electron, Inc.), and 994–
75409 (Wako Chemicals). The lipid distribution in plasma lipoprotein
fractions was assessed by fast-performance liquid chromatography gel
filtration with a Superose 6 HR 10/30 column (Pharmacia).27 Plasma
values of VCAM-1 (MVC00) and ICAM-1 (MIC100; R&D) were
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determined using ELISA, and TGF-b, IFNg, IL-6, IL-10, and mKC using
multiplex array systems (Becton, Dickinson and Company).
Flow cytometry
For blood and spleen FACS analyses, single cell suspensions were incu-
bated with antibodies against CD4, CD8, B220, CD11c, CD11b,
CD62L, CD44, and CD25 (BD Pharmingen) and then cells were ana-
lysed with a FACSCantoII (BD Pharmingen) and FACSDiva software.
Post-acquisition analysis was done with FACSDiva (BD Pharmingen)
or FlowJo7 software (Tree Star).
Statistical analysis
Data are presented as mean+ SEM. The en face ORO quantifications
were analysed with a non-parametric Mann–Whitney U-test. Statistical
significance of differences was calculated using an ANOVA with post
hoc Tukey’s test or Student unpaired t-test. Significance was accepted
at the level of P, 0.05.
Results
SIRT1 protects against atherosclerosis
To address the role of SIRT1 in atherogenesis, we compared SIRT1
expression in aortic lysates obtained from atherosclerotic
ApoE2/2 and normal wild-type (WT) mice. Aortic SIRT1 protein
expression was lower in ApoE2/2 than in WT mice (see Sup-
plementary material online, Figure S1A), suggesting a protective
role of SIRT1 in atherogenesis. In order to establish a cause–
effect relationship between SIRT1 expression and atherosclerosis,
we applied genetic deletion of SIRT1 in atherosclerotic mice. For
this purpose, we compared 20-week-old male ApoE2/2
SIRT1+/+ and ApoE2/2 SIRT1+/2 mice that were kept on a high-
cholesterol diet for 12 weeks (see Supplementary material
online, Figure S2A). Of note, SIRT1 expression is only slightly
reduced in WT mice treated with a high-cholesterol diet (see
Figure 1 SIRT1 protects mice against atherosclerosis. (A) En face Oil red O (ORO) staining of thoraco-abdominal aortae and quantifications
of plaque area. n ¼ 9, ApoE2/2 SIRT1+/+(B); n ¼ 11, ApoE2/2 SIRT1+/2(A). (B) Representative images for Massons trichrome and Elastica van
Gieson stainings from animals with comparable plaque sizes. Magnification: X 40. *P, 0.05.
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Supplementary material online, Figure S1B). To examine any SIRT1
compensation for the missing SIRT1 allele, we assessed
SIRT1 expression in aortic lysates of the two genotypes. Aortic
SIRT1 protein in ApoE2/2 SIRT1+/2 mice amounted to about
60% of protein in ApoE2/2 SIRT1+/+ mice (see Supplementary
material online, Figure S1C). Importantly, en face plaque quantifi-
cations in thoraco-abdominal aortae and in serial cross sections
of aortic roots revealed fewer atherosclerotic plaques in
ApoE2/2 SIRT1+/+ compared with ApoE2/2 SIRT1+/2 mice
(Figures 1A and 2). Massons trichrome and van Gieson stainings
revealed that total collagen content, necrotic core size, and
fibrous cap thickness did not differ between the two groups
(Figure 1B, see Supplementary material online, Figure S1D–F). No
difference was observed in the amount of apoptotic cells (see Sup-
plementary material online, Figure S1F). These findings indicate that
endogeneous SIRT1 protects against atherosclerosis.
Accumulation of plaque macrophages
and T cells is reduced by SIRT1
Accumulation of macrophages and T cells in the subintimal space
plays a central role in atherogenesis.1 Our analyses revealed
increased accumulation of macrophages and T cells in athero-
sclerotic plaques of ApoE2/2 SIRT1+/2 compared with ApoE2/2
SIRT1+/+ mice (Figure 2). SIRT1 staining in aortae of healthy WT
mice or ApoE2/2 mice under normal diet showed that SIRT1 is
expressed in smooth muscle and endothelial cells (see
Supplementary material online, Figure S3A). In diseased aortae
from ApoE2/2 mice under high-cholesterol diet, SIRT1 is also
expressed in cells within the plaques (see Supplementary material
online, Figure S3A). Double stainings revealed that SIRT1 is
expressed in both plaque endothelial cells and macrophages in dis-
eased ApoE2/2 aortae (see Supplementary material online, Figure
S3B).
SIRT1 in macrophages is sufficient to
reduce foam cell formation and
atherogenesis
We observed no difference neither in fasted nor fed plasma
glucose or insulin levels, total body or epididymal fat weight (see
Supplementary material online, Figure S4) and found no difference
in total cholesterol and its subfractions between ApoE2/2
SIRT1+/+ and ApoE2/2 SIRT1+/2 mice (see Supplementary
material online, Figure S5 and Table S1). Further, plasma cytokine
levels were similar in the two genotypes (see Supplementary
material online, Table S2). Since inflammatory factors from WAT
may enhance atherogenesis,28,29 we examined the expression of
several adipokines and adipose-derived hormones in epididymal
WAT. Expression of Adiponectin (Adipoq), Leptin, Visfatin (Nampt),
Chemerin (Rarres2), Resistin (Retn) were equivalent, whereas
expression of Plasminogen activator inhibitor 1 (PAI-1 or Serpine1)
was slightly, but not significantly elevated in ApoE2/2 SIRT1+/2
compared with ApoE2/2 SIRT1+/+ epididymal WAT (see
Figure 2 SIRT1 deletion increases macrophage and T-cell accumulation in plaques. Immunohistochemistry with quantifications of Oil red O
(ORO), CD68, andCD3 (arrows) on plaques from aortic sinus. Magnifications:Oil redO, CD68:×40; CD3:×400. n ¼ 6 per genotype. *P, 0.05.
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Supplementary material online, Figure S6). These data do not
exclude a contribution of systemic inflammatory factors such as
WAT, but suggest that the damaging effects of partial SIRT1
deficiency are mainly mediated via inflammatory cells localized in
plaques.
Therefore, we focused on the role of SIRT1 in macrophages.
Foam cell formation is a crucial step in atherogenesis.1 We
observed no difference in basal LDL uptake in peritoneal-elicited
macrophages from ApoE2/2 SIRT1+/2 compared with ApoE2/2
SIRT1+/+ mice, but found enhanced uptake upon stimulation
with oxLDL (Figure 3A). Pharmacological inhibition of SIRT1 with
splitomicin in RAW 264.7 macrophages showed a trend towards
increasing oxLDL uptake (see Supplementary material online,
Figure S7). Consistently, siRNA-induced SIRT1 knockdown
increased uptake of oxLDL in RAW 264.7 macrophages compared
with control cells (Figure 3B and C ). To study a potential role of
CD36 in oxLDL uptake, we blocked CD36-mediated oxLDL
uptake using an anti-CD36 antibody in scrambled or
SIRT1-siRNA-treated macrophages. Neutralization of CD36
decreased uptake of oxLDL by 50% compared with non-
neutralized cells (Figure 3C). A higher elevation of oxLDL uptake
was observed in SIRT1-siRNA-treated macrophages with
additional CD36 neutralization, but did not reach significance
difference compared with any other group (Figure 3C). These
Figure 3 SIRT1 reduces foam cell formation. (A) Increased uptake of oxLDL in peritoneal thioglycolate-elicited macrophages from ApoE2/2
SIRT1+/2 compared with ApoE2/2 SIRT1+/+ mice. oxLDL uptake is given as the ratio of the percentage of ORO-positive area divided by the
percentage of total cell area in at least 150 cells per genotype. (B) siRNA-induced SIRT1 knockdown increases uptake of oxLDL in RAW 264.7
macrophages compared with scr-siRNA-treated cells. (C) siRNA-mediated SIRT1 silencing in 5 h TNFa-pretreated RAW 264.7 macrophages:
left panel, expression of Lox-1; right panel, uptake of oxLDL in neutralizing anti-CD36 antibody-treated cells. *P, 0.05. ***P, 0.001. Magni-
fications: ×400.
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data suggest that SIRT1 exerts CD36-dependent and -independent
effects in oxLDL uptake.
To examine whether an SIRT1-dependent mechanism in macro-
phages accounts for decreased atherosclerosis in vivo, we per-
formed bone marrow transplantation experiments. Bone marrow
from ApoE2/2 SIRT1+/2 or ApoE2/2 SIRT1+/+ mice was trans-
planted into irradiated 6-week-old ApoE2/2 mice (see Supplemen-
tary material online, Figure S2B), respectively. Flow cytometry
analyses of blood and spleen samples from transplanted mice
revealed an increased number of blood monocytes of ApoE2/2
recipient mice receiving ApoE2/2 SIRT1+/2 bone marrow cells,
but no proportional difference in T-cell subtypes, MHCII+ cells,
B cells or macrophages (see Supplementary material online,
Figure S8). Chimeric ApoE2/2 recipient mice receiving ApoE2/2
SIRT1+/2 bone marrow showed more atherosclerotic lesions
compared with mice transplanted with ApoE2/2 SIRT1+/+ bone
marrow (Figure 4). These findings support the notion that SIRT1
function in macrophages is sufficient to decrease atherogenesis.
Deacetylation of RelA/p65 by SIRT1
diminishes Lox-1 expression
Active uptake of modified cholesterol in macrophages is mainly
regulated by SR-A, SR-B, CD36, and Lox-1,30 whereas cholesterol
efflux is driven by ATP-binding cassette transporters.31 Expression
of CD36, SR-A, and SR-B was not altered (see Supplementary
material online, Figure S9), whereas Lox-1 expression was higher
in ApoE2/2 SIRT1+/2 aortic lysates (Figure 5A). Because expression
of Lox-1 in SIRT1-siRNA-treated macrophages was increased
(Figure 3C), we planned to study the SIRT1–Lox-1 pathway
more in detail. Deletion of Lox-1 has been shown to reduce ather-
osclerosis in mice.32 Since Lox-1 is an NF-kB target33 and SIRT1
deacetylates RelA/p65 in murine macrophages,34 we compared
Lox-1 RNA levels in TNFa-stimulated RAW 264.7 cells pretreated
with splitomicin. We observed an increase in Lox-1 expression in
splitomicin-treated macrophages compared with untreated
control cells (Figure 5B). These data suggest that SIRT1 suppresses
NF-kB signalling in macrophages, thereby reducing Lox-1
expression and oxLDL uptake.
To get more insight into the molecular events underlying SIRT1-
dependent NF-kB deacetylation in murine cells, we analysed
SIRT1 expression in different MEF cell lines. Ectopic expression of
SIRT1 in SIRT12/2 MEF reduced Lox-1 expression upon TNFa treat-
ment (Figure 5C). In RelA/p652/2 MEF with reconstituted wt-RelA/
p65 expression,26 siRNA-induced SIRT1 knockdown enhanced
Lox-1 expression upon TNFa stimulation. In contrast, SIRT1-siRNA
had no effect on Lox-1 expression in TNFa-stimulated RelA/p652/2
MEF with reconstituted non-acetylatable K310R-mutant-RelA/p6526
(Figure 5D). These data show that SIRT1-dependent deacetylation of
RelA/p65 at K310 is sufficient to reduce Lox-1 gene expression.
Several reports show a link between Lox-1 and matrix metallo-
proteinases (MMPs) that are expressed and secreted by human
endothelial cells, including the collagenase MMP1, stromelysin-1
(MMP3), the membrane type 1 MMP (MT1-MMP or MMP14),
and the tissue inhibitor of metalloproteinase 3 (TIMP3).35–38 To
investigate if metalloproteinase expression is affected by SIRT1,
we quantified aortic expression of MMP13, MMP3, MMP8,
MMP9,MMP14, and TIMP3. No significant change in the expression
of these MMPs was observed in ApoE2/2 SIRT1+/2 compared with
ApoE2/2 SIRT1+/+ aortae (see Supplementary material online,
Figure S10), indicating that the phenotype of ApoE2/2 SIRT1+/2
mice is not related to SIRT1–Lox-1-mediated expression of MMPs.
Atheroprotective effects of SIRT1 do not
affect cholesterol efflux
When examining cholesterol efflux, we found that expression of
ABCA1 was not altered in aortic lysates from ApoE2/2 SIRT1+/2
compared with ApoE2/2 SIRT1+/+ mice (see Supplementary
material online, Figure S11A). Similarly, expression levels of ABCA1
and ABCG1 were not different in peritoneal macrophages from
ApoE2/2 SIRT1+/+ and ApoE2/2 SIRT1+/2 mice (see Supplemen-
tary material online, Figure S11B). Cholesterol efflux assays in
RAW 264.7 macrophages treated with splitomicin revealed no
ApoA-I-dependent changes (see Supplementary material online,
Figure S11C). Furthermore, we detected no difference in aortic
expression of the ABCA1 regulators LXRa, PPARg, or its coactiva-
tor PGC-1a (PPARg coactivator 1a) (see Supplementary material
online, Figure S11D–F). These data suggest that aortic cholesterol
efflux is not affected by SIRT1 in atherosclerotic mice.
Figure 4 SIRT1 function in macrophages is sufficient to
decrease atherogenesis. Chimeric ApoE2/2 mice that received
ApoE2/2 SIRT1+/2 (n ¼ 7) bone marrow cells develop more
atherosclerosis than those which received ApoE2/2 SIRT1+/+
(n ¼ 5) bone marrow cells. *P, 0.05.
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Discussion
Recently, SIRT1 has been shown to decrease atherosclerosis by
improving endothelium-dependent vascular function in ApoE2/2
mice with an endothelial SIRT1 overexpression that were kept
on a high-fat diet.20 Our study shows that endogenous SIRT1 pre-
vents macrophage foam cell formation in atherogenesis indepen-
dently of systemic lipid levels. We demonstrate that loss of a
single SIRT1 allele in ApoE2/2 SIRT1+/2 mice is sufficient to
increase plaque formation.
Macrophage-derived foam cell formation is enhanced upon a
relative increase in cholesterol uptake or by a defective cholesterol
efflux, respectively.39 Our in vitro foam cell assay reveals that SIRT1
activation diminishes oxLDL uptake in peritoneal macrophages.
Among the receptors that may account for this increased LDL
uptake by macrophages, we identified Lox-1 to be critically
involved: SIRT1 inhibits TNFa-induced expression of Lox-1 in
macrophages. In fact, the Lox-1 promoter contains NF-kB binding
sites and is expressed upon TNFa stimulation.33 Using RelA/
p652/2 MEF, we could further show that the deacetylation of
RelA/p65 by SIRT1 suppresses Lox-1 expression. We acknowledge
that the final proof of a Lox-1-mediated effect on foam cell for-
mation would require additional evidence from genetic
loss-of-function or neutralizing antibody experiments. These ques-
tions need to be addressed in future studies.
To test whether an SIRT1-dependent mechanism in bone
marrow-derived cells accounts for the increase in atherosclerosis
in vivo, we performed bone marrow transplantation experiments.
Chimeric ApoE2/2 mice receiving ApoE2/2 SIRT1+/2 bone
marrow showed increased atherosclerotic plaques compared
with mice receiving ApoE2/2 SIRT1+/+ bone marrow. These find-
ings demonstrate that partial SIRT1 deletion in bone marrow-
derived macrophages is sufficient to enhance atherogenesis.
The role of NF-kB in plaque macrophages and lipoprotein
uptake in atherogenesis is controversial. Disruption of NF-kB sig-
nalling by partial IKK2 deletion in macrophages increased athero-
sclerosis.40 Conversely, studies using macrophage-specific p50
deletion or a dominant-negative IkBa mutant to disrupt NF-kB sig-
nalling, resulted in smaller atherosclerotic lesions and diminished
uptake of lipoproteins.41,42 Since NF-kB and its transcriptional
activity are tightly regulated,43,44 pharmacological modulation of
an upstream regulator of NF-kB seems more promising in prevent-
ing atherogenesis than direct NF-kB modulation.45 Our study
shows that SIRT1 might be an attractive modulator, since its inter-
ference with the NF-kB signalling pathway exerts beneficial effects
on plaque formation.
Several reports suggest that other SIRT1 targets may also con-
tribute to atherogenesis. For instance, PPARg, a key transcription
factor in adipocyte differentiation, plays a pivotal role in macro-
phages and modulates the extent of atherosclerosis.14 Both
PPARg and its target LXR are regulated by SIRT1 in adipocytes
and macrophages.5,46 Interestingly, Li et al.46 showed reduced
cholesterol efflux in primary macrophages from SIRT12/2 com-
pared with SIRT1+/+ mice. We could neither observe a difference
Figure 5 Deacetylation of RelA/p65 by SIRT1 diminishes Lox-1 expression. (A) Aortic Lox-1 expression is increased in ApoE2/2 SIRT1+/2 com-
pared with ApoE2/2 SIRT1+/+ mice. (B) Lox-1 expression is higher in 5 h TNFa-stimulated RAW 264.7 macrophages pretreated with 200 mM
splitomicin (Splito) compared with untreated cells (nt). (C) Ectopic SIRT1 expression in SIRT12/2 MEF reduces Lox-1 expression. (D) In RelA/
p652/2 MEF with reconstituted wt-RelA/p65, siRNA-mediated SIRT1 knockdown enhances Lox-1 expression upon 5 h TNFa stimulation,
whereas no effect is observed in RelA/p652/2 MEF with a reconstituted mutated, non-acetylatable K310-RelA/p65. *P, 0.05; ***P, 0.001.
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in the aortic expression of ABCA1, ABCG1, PPARg, or LXRa nor
an ApoA-I-dependent decrease in cholesterol efflux upon splitomi-
cin treatment in RAW 264.7 macrophages. Possibly, the effect of a
single missing SIRT1 allele is not sufficient to affect cholesterol
efflux in atherosclerotic mice.
Taken together, our results reveal a novel mechanism by which
SIRT1 prevents atherogenesis: SIRT1 suppresses NF-signalling by
deacetylating RelA/p65, thereby reducing Lox-1 expression and
diminishing uptake of oxLDL and foam cell formation. Given the
availability of specific SIRT1-activating drugs that are being tested
in clinical trials in patients with type 2 diabetes, pharmacological
activation of SIRT1 may also become an attractive anti-atherogenic
strategy by preventing macrophage foam cell formation.47
Supplementary material
Supplementary material is available at European Heart Journal
online.
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A 52-year-old man presented with arterial
hypertension and 1-year history of progressive
shortness of breath, fatigue and abdominal swel-
ling. Physical examination revealed hypotension,
tachycardia, muffled heart sounds, distension of
the jugular veins with Kussmaul’s sign and
ascites. Blood pressure was 90/75 mmHg and
heart rate was 100 b.p.m. Laboratory tests,
including inflammatory markers and kidney func-
tion were normal. Tuberculosis was also
excluded. ECG showed sinus tachycardia with
P-mitrale and low QRS voltage. Chest X-ray
revealed dense pericardial calcification (Panel
A). A transthoracic echocardiography was con-
ducted with very poor acoustic window and
was positive only for diastolic dysfunction. Multi-
detector computed cardiac tomography scans of
the chest revealed diffuse thickening and calcifi-
cation involving both the visceral and parietal
pericardium of right and left ventricles (RV, LV)
(Panel B, arrows) and confirmed the diagnosis
of constrictive pericarditis. Volume rendering
reconstruction of cardiac structures showed
dense pericardial calcification predominantly over both the ventricles resembling heart made with porcelain (Panels C and D). The
patient was qualified for surgical pericardiectomy, which resulted in immediate normalization of cardiac function. The calcified peri-
cardium was presumed to be owing to misdiagnosed chronic pericarditis.
Panel A. Chest X ray (postero-anterior view) showing pericardial calcification.
Panel B. Multidetector computed cardiac tomography showing diffuse thickening and calcification of the pericardium (arrows).
Panels C and D. Volume rendering reconstruction of cardiac structures showing dense pericardial calcification predominantly over
both the ventricles (‘pottery heart’).
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